Lineage Cell Therapeutics, Inc. (TLV: LCTX)

Market Cap	620.89M
Revenue (ttm)	32.41M
Net Income (ttm)	-74.76M
Shares Out	n/a
EPS (ttm)	-0.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,249
Open	352.70
Previous Close	352.70
Day's Range	352.70 - 372.30
52-Week Range	3.03 - 372.30
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 7, 2024

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic c...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1990
• Employees: 75
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: LCTX

Financial Performance

In 2023, Lineage Cell Therapeutics's revenue was $8.95 million, a decrease of -39.16% compared to the previous year's $14.70 million. Losses were -$21.49 million, -18.22% less than in 2022.

Financial numbers in USD